Clinical Trial Update: Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

This document describes a Phase II clinical trial of Ivonescimab, an anti-PD-1/VEGF bispecific antibody, in patients with previously treated metastatic colorect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: RECRUITING